Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 12/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16700558 | 0.81 | PDCD1 (0.52) | PDCD1CD274 | |
| SCHEMBL29831821 | 0.78 | GRM5 (0.53) | GRM5KCNH2 | |
| SCHEMBL29050018 | 0.78 | GRM5 (0.53) | GRM5KCNH2 | |
| SCHEMBL30605079 | 0.77 | GRM5 (0.52) | GRM5KCNH2 | |
| SCHEMBL16682688 | 0.77 | PDCD1 (0.54) | GRM5PDCD1CD274JAK2JAK1 | |
| SCHEMBL29050010 | 0.75 | GRM5 (0.50) | GRM5KCNH2 | |
| SCHEMBL29514224 | 0.75 | GRM5 (0.50) | GRM5KCNH2 | |
| SCHEMBL16699354 | 0.75 | PDCD1 (0.58) | PDCD1CD274 | |
| SCHEMBL17925497 | 0.75 | WNT1 (0.46) | GRM5PDCD1CD274 | |
| SCHEMBL30605074 | 0.74 | GRM5 (0.49) | GRM5KCNH2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160318933-A1 | FUSED PYRAZOLE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-11-03 | — | — | US | disclosed |
| US-20160318933-A1 | FUSED PYRAZOLE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318933-A1 | FUSED PYRAZOLE DERIVATIVE | DRD4, DRD2, DRD3 | GRM5 185/4885KCNH2 617/4885PDCD1 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.